Global Head and Neck Squamous Cell Carcinoma (HNSCC)

Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market Research Report: Forecast (2022-27)

By Diagnosis (Blood Tests, Biopsy, Biomarker Testing, Nasopharyngolaryngoscopy, Imaging (X-ray, CT/PET Scan, MRI)), By Treatment (Surgery, Radiation Therapy, Chemotherapy, (Docetaxel, Cisplatin, 5-Flu Read more

  • Healthcare
  • Jul 2022
  • 195
  • HC22096

Market Definition

HNSCC (Head & Neck Squamous Cell Carcinoma) is cancer that develops in mucous membranes of the mouth, throat, & nose and showcases severe symptoms like:

  • Abnormal patches or open sores in the mouth & throat
  • Unusual pain & bleeding in the mouth
  • Difficulties in breathing, etc.

The Oral Cavity, Paranasal Sinuses, Nasal Cavity, Oropharynx, Larynx, Hypopharynx, & Nasopharynx are various locations where HNSCC can occur. In case of late detection or non-treatment, it can also spread across other parts like the lungs or lymph nodes, making the situation fatal. Hence, with the criticality of addressing such health conditions, several governments & prominent biopharma companies are actively participating in various research & development activities to bring innovations in therapeutics and cater to the unmet patient needs worldwide.  

Market Insights

The Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market is projected to grow at around 9.5% CAGR during the forecast period, i.e., 2022-27. The growth of the market is driven primarily by the mounting prevalence of HNSCC, i.e., augmenting the demand for diagnosis & treatment and, in turn, instigating governments of different countries to increase their respective healthcare expenditures for drug developments to cater to the high unmet requirements of patients worldwide.

Report Coverage Details
Study Period Historical Data: 2017-20
Base Year: 2021
Forecast Period: 2022-27
CAGR 9.5%
Regions Covered North America: The US, Canada, Mexico
South America: Brazil, Rest of Latin America
Europe: Germany, The UK, France, Italy, Spain, Rest of Europe
Middle East & Africa: GCC, South Africa, Rest of Middle East and Africa 
Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific
Key Companies Profiled AbbVie Inc., AstraZeneca PLC, Amgen Inc., Bayer AG, Bristol Myers Squibb, DFG Oncology, Dr. Reddy’s Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche AG, Jiangsu Hengrui, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Others
Unit Denominations USD Million/Billion

 

As several countries are laying out favorable policies for the research & development and clinical trials of novel drugs, the global market is observing the active participation of the leading players. The primary causes of HNSCC include smoking, alcohol consumption, HPV (Human Papillomavirus) infection for oropharyngeal cancer, & EBV (Epstein-Barr Virus) infection for nasopharyngeal cancer.

Governments worldwide are encouraging several research institutions to indulge immensely in developing effective chemotherapy & immunotherapy drugs for the treatment of HNSCC patients. Moreover, they are also spreading awareness among people about the ill effects of smoking & alcohol consumption and the availability of effective diagnosis & treatment for HNSCC. 

Additionally, they are massively investing in the oncology sector, pharmaceutical giants, cancer associations, and other organizations for the research & development associated with HNSCC therapeutics, thereby generating lucrative opportunities for the various companies participating in the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market. 

Moreover, as treatments like chemotherapy are being adopted extensively by patients across different corners of the world, the demand for drugs like Docetaxel, Cisplatin, & Bleomycin, among others, is rising swiftly and, in turn, instigating the leading biopharma companies to increase their production & distribution capacities in order to cater to the high unmet patient needs

  1. Introduction
    1. Research Process
    2. Assumption
    3. Market Segmentation
    4. Market Definition
  2. Executive Summary
  3. Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market Trends & Insights
  4. Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market Regulation & Policy, By Country
  5. Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market Dynamics
    1. Growth Drivers
    2. Challenges
    3. Impact Analysis
  6. Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market Hotspot and Opportunities
  7. Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
        1. Blood Tests
        2. Biopsy
        3. Biomarker Testing
        4. Nasopharyngolaryngoscopy
        5. Imaging (X-ray, CT/PET Scan, MRI)
      2. By Treatment
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
          1. Docetaxel
          2. Cisplatin
          3. 5-Flurouracil
          4. Methotrexate
          5. Others (Bleomycin, etc.)
        4. Immunotherapy
          1. Keytruda (Pembrolizumab)
          2. Opdivo (Nivolumab)
        5. Targeted Therapy
          1. Cetuximab
        6. Others (Combination Therapy, etc.)
      3. By End-User
        1. Hospitals
        2. Clinics
        3. Specialty Cancer Centers
      4. By Region
        1. North America
        2. South America
        3. Europe
        4. Middle East & Africa
        5. Asia-Pacific
      5. By Company
        1. Competition Characteristics
        2. Revenue Shares
        3. Competitor Placement in MarkNtel Advisor’s Quadrant
  8. North America Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. The US
        2. Canada
        3. Mexico
  9. South America Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. Brazil
        2. Rest of Latin America
  10. Europe Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. The UK
        2. Germany
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
  11. Middle East & Africa Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. South Africa
        2. GCC
        3. Rest of Middle East & Africa
  12. Asia-Pacific Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. China
        2. Japan
        3. India
        4. Australia
        5. South East Asia
        6. Rest of Asia-Pacific
  13. Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market Key Strategic Imperatives for Success and Growth
  14. Competitive Outlook
    1. Competition Matrix
      1. By Application Portfolio
      2. Brand Specialization
      3. Target Markets
      4. Target by Applications
      5. Research & Development
      6. Strategic Alliances
      7. Strategic Initiatives
    2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
      1. AbbVie Inc.
      2. AstraZeneca PLC
      3. Amgen Inc.
      4. Bayer AG
      5. Bristol Myers Squibb
      6. DFG Oncology
      7. Dr. Reddy’s Laboratories
      8. Eli Lilly and Company
      9. F. Hoffmann-La Roche AG
      10. Jiangsu Hengrui
      11. Merck & Co., Inc.
      12. Novartis International AG
      13. Pfizer Inc.
      14. Sanofi S.A.
      15. Others
  15. Disclaimer
Head and Neck Squamous Cell Carcinoma (HNSCC) Market Segmentation
*This field is required